Travere Therapeutics, Inc. TVTX Tiopronin products — Total Revenue
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Travere Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Travere Therapeutics, Inc.’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about Travere Therapeutics, Inc.'s tiopronin products — total revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Travere Therapeutics, Inc.'s tiopronin products — total revenue?
- Travere Therapeutics, Inc. (TVTX) reported tiopronin products — total revenue of $19.34M in Q1 2026.
- How has Travere Therapeutics, Inc.'s tiopronin products — total revenue changed year-over-year?
- Travere Therapeutics, Inc.'s tiopronin products — total revenue decreased by 3.2% year-over-year, from $19.98M to $19.34M.
- What is the long-term trend for Travere Therapeutics, Inc.'s tiopronin products — total revenue?
- Over 4 years (2021 to 2025), Travere Therapeutics, Inc.'s tiopronin products — total revenue has grown at a -6.4% compound annual growth rate (CAGR), from $115.12M to $88.46M.
- What does tiopronin products — total revenue mean?
- This metric represents the total gross revenue generated from the sale of the company's specific portfolio of tiopronin-based therapeutic products. It serves as a key indicator of the market performance and commercial lifecycle of this established product line within the rare disease segment. Tracking this figure allows investors to assess the stability and contribution of legacy assets to the company's overall top-line financial health.